Immunization with the cysteine proteinase Ldccys1 gene from Leishmania (Leishmania) chagasi and the recombinant Ldccys1 protein elicits protective immune responses in a murine model of visceral leishmaniasis

Vaccine

Volumn 26, Issue 5, 2008, Pages 677-685

  Ferreira, Josie Haydée L ^a,b   Gentil, Luciana Girotto ^a   Dias, Suzana Souza ^a   Fedeli, Carlos Eduardo C ^a   Katz, Simone ^a   Barbiéri, Clara Lúcia ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Faculdade NOVAFAPI   (Brazil)

Author keywords

Cysteine proteinase; Leishmania (Leishmania) chagasi; Visceral leishmaniasis

Indexed keywords

BCG VACCINE; CYSTEINE PROTEINASE; CYSTEINE PROTEINASE LDCCYS1; GAMMA INTERFERON; LEISHMANIA VACCINE; NITRIC OXIDE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DNA IMMUNIZATION; FEMALE; GENE EXPRESSION; GENE MUTATION; IMMUNE RESPONSE; IMMUNIZATION; LEISHMANIA CHAGASI; LEISHMANIASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; CELLS, CULTURED; CYSTEINE ENDOPEPTIDASES; FEMALE; GENES, PROTOZOAN; IMMUNIZATION SCHEDULE; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; INTERFERON TYPE II; LEISHMANIA; LEISHMANIASIS; LEISHMANIASIS VACCINES; MICE; MYCOBACTERIUM BOVIS; NITRIC OXIDE; PLASMIDS; PROPIONIBACTERIUM ACNES; PROTOZOAN PROTEINS; SPLEEN; VACCINATION; VACCINES, SYNTHETIC;

EID: 37849026965     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.11.044     Document Type: Article

References (66)

1. Mauricio I.L., Stothard J.R., and Miles M.A. The strange case of Leishmania chagasi. Parasitol Today 16 (2000) 188-189
2. World Health Organization. Leishmaniasis. Fourteenth Program Report. UNDP/World Bank/Special Program for Research and Training in Tropical Diseases (TDR). Tropical Disease Research Progress 1997-1998. Geneva: World Health Organization; 1999, p. 1-6.
3. Arias J.R., Monteiro P.S., and Zicker F. The reemergence of visceral leishmaniasis in Brazil. Emerg Infect Dis 2 (1996) 145-146
4. Pintado V., and López-Vélez R. HIV-associated visceral leishmaniasis. Clin Microbiol Infect 7 (2000) 291-300
5. Carvalho E.M., Barral A., Pedral-Sampaio D., Barral-Netto M., Badaró R., Rocha H., et al. Immunologic markers of clinical evolution in children recently infected with Leishmania donovani chagasi. J Infect Dis 165 (1992) 535-540
6. Kaye P.M., Curry A.J., and Blackwell J.M. Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis. J Immunol 146 (1991) 2763-2770
7. Murray H.W. Effect of continuous administration of interferon-γ in experimental visceral leishmaniasis. J Infect Dis 161 (1990) 992-994
8. Murray H.W., Stern J.J., Welte K., Rubin B.Y., Carriero S.M., and Nathan C.F. Experimental visceral leishmaniasis: production of interleukin 2 and interferon-γ, tissue immune reaction, and response to treatment with interleukin 2 and interferon-γ. J Immunol 138 (1987) 2290-2297
9. Squires K.E., Schreiber R.D., McElraith M.J., Rubin B.Y., Anderson S.L., and Murray H.W. Experimental visceral leishmaniasis: role of endogenous IFN-γ in host defense and tissue granulomatous response. J Immunol 143 (1989) 4244-4249
10. Wilson M.E., Young B.M., Andersen K.P., Weinstock J.V., Metwali A., Ali K.M., et al. A recombinant Leishmania chagasi antigen that stimulates cellular immune responses in infected mice. Infect Immun 63 (1995) 2062-2069
11. Dole V.S., Raj V.S., Ghosh A., Madhubala R., Myler P.J., and Stuart K.D. Immunization with recombinant LD1 antigens protects against experimental leishmaniasis. Vaccine 19 (2001) 423-430
12. Jaffe C.L., Rachamim N., and Sarfstein R. Characterization of two proteins from Leishmania donovani and their use for vaccination against visceral leishmaniasis. J Immunol 144 (1990) 699-706
13. Jardim A., Tolson D.L., Turco S.J., Pearson T.W., and Olafson R.W. The Leishmania donovani lipophosphoglycan T lymphocyte-reactive component is a tightly associated protein complex. J Immunol 147 (1991) 3538-3544
14. Palatnik-de-Sousa C.B., Paraguai-de-Souza E., Gomes E.M., and Borojevic R. Experimental murine Leishmania donovani infection: immunoprotection by the fucose-mannose ligand (FML). Braz J Med Biol Res 27 (1994) 547-551
15. Paraguai de Souza E., Bernardo R.R., Palatnik M., and Palatnik de Sousa C.B. Vaccination of BALB/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani. Vaccine 19 (2001) 3104-3115
16. ®adjuvant. Vaccine 20 (2002) 3292-3303
17. Skeiky Y.A.W., Kennedy M., Kaufman D., Borges M.M., Guderian J.A., Scholler J.K., et al. LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile. J Immunol 161 (1998) 6171-6179
18. Stäger S., Smith D.F., and Kaye P.M. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. J Immunol 165 (2000) 7064-7071
19. Streit J.A., Recker T.J., Donelson J.E., and Wilson M.E. BCG expressing LCR1 of Leishmania chagasi induces protective immunity in susceptible mice. Exp Parasitol 94 (2000) 33-41
20. Gurunathan S., Prussin C., Sacks D.L., and Seder R.A. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nat Med 4 (1998) 1409-1415
21. Gurunathan S., Sacks D.L., Brown D.R., Reiner S.L., Charest H., Glaichenhaus N., et al. Vaccination with DNA encoding the immunodominat LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J Exp Med 186 (1997) 1137-1147
22. Sjolander A., Baldwin T.M., Curtis J.M., Bengtsson K.L., and Handman E. Vaccination with recombinant parasitic surface antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection. Vaccine 16 (1998) 2077-2084
23. Walker P.S., Scharton-Kersten T., Rowton E.D., Hengge U., Bouloc A., Udey M.C., et al. Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis. Hum Gene Ther 9 (1998) 1899-1907
24. Xu D., and Liew F.Y. Protection against leishmaniasis by injection of DNA encoding a major surface glycoprotein, gp63, of L. major. Immunology 84 (1995) 173-176
25. Gonzalo R.M., Real G., Rodríguez J.R., Rodríguez D., Heljasvaara R., Lucas P., et al. A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum P36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis. Vaccine 20 (2002) 1226-1231
26. Lange U.G., Mastroeni P., Blackwell J.M., and Stober C.B. DNA-Salmonella enterica serovar Typhimurium primer-booster vaccination biases towards T helper 1 responses and enhances protection against Leishmania major infection in mice. Infect Immun 72 (2004) 4924-4928
27. Tewary P., Jain M., Sahani M.H., Saxena S., and Madhubala R. A heterologous prime-boost vaccination regimen using ORFF DNA and recombinant ORFF protein confers protective immunity against experimental visceral leishmaniasis. J Infect Dis 191 (2005) 2130-2137
28. Beyrodt C.G.P., Pinto A.R., Freymüller E., and Barbiéri C.L. Characterization of an antigen from Leishmania amazonensis amastigotes able to elicit protective responses in a murine model. Infect Immun 65 (1997) 2052-2059
29. Pinto A.R., Beyrodt C.G.P., Lopes R.A., and Barbiéri C.L. Identification of a 30 kDa antigen from Leishmania (L.) chagasi amastigotes implicated in protective cellular responses in a murine model. Int J Parasitol 30 (2000) 599-607
30. Rafati S., Salmanian A.H., Taheri T., Vafa M., and Fasel N. A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major. Vaccine 19 (2001) 3369-3375
31. Rafati S., Zahedifard F., and Nazgouee F. Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis. Vaccine 24 (2006) 2169-2175
32. Rafati S., Nakhaee A., Taheri T., Taslimi Y., Darabi H., Eravani D., et al. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinase type I and II of L. infantum. Vaccine 23 (2005) 3716-3725
33. Pinheiro P.H.C., Dias S.S., Eulálio K.D., Mendonça I.L., Katz S., and Barbieri C.L. Recombinant cysteine proteinase from Leishmania (Leishmania) chagasi implicated in human and dog T-cell responses. Infect Immun 73 (2005) 3787-3789
34. Dias S.S., Pinheiro P.H.C., Katz S., Santos M.R.M., and Barbieri C.L. A recombinant cysteine proteinase from Leishmania (Leishmania) chagasi suitable for serodiagnosis of American visceral leishmaniasis. Am J Trop Med Hyg 72 (2005) 126-132
35. Barbiéri C.L., Doine A.I., and Freymüller E. Lysosomal depletion in macrophages from spleen and foot lesions of Leishmania-infected hamster. Exp Parasitol 71 (1990) 218-228
36. Sambrook J., Fritsch E.F., and Maniatis T. Molecular cloning: a laboratory manual (1989), Cold Spring Harbor Laboratory Press, New York
37. Buffet P.A., Sulahian A., Garin Y.J., Nassar N., and Derouin F. Culture microtitration: a sensitive method for quantifying Leishmania infantum in tissues of infected mice. Antimicrob Agents Chemother 39 (1995) 2167-2168
38. Ghosh A., Zhang W.W., and Matlashewski G. Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections. Vaccine 20 (2001) 59-66
39. Molano I., Alonso M.G., Mirón C., Redondo E., Requena J.M., Soto M., et al. A Leishmania infantum multi-component antigenic protein mixed with live BCG confers protection to dogs experimentally infected with L. infantum. Vet Immunol Immunopathol 92 (2003) 1-13
40. Santos W.R., Lima V.M.F., Paraguai de Souza E., Bernardo R.R., Palatnik M., and Palatnik de Sousa C.B. Saponins, IL-12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis. Vaccine 21 (2002) 30-43
41. Miralles G.D., Stoeckle M.Y., McDermott D.F., Finkelman F.D., and Murray H.W. Th1 and Th2 cell-associated cytokines in experimental visceral leishmaniasis. Infect Immun 62 (1994) 1058-1063
42. Saha B., Basak S.K., and Roy S. Immunobiological studies on experimental visceral leishmaniasis. III. Cytokine-mediated regulation of parasite replication. Scand J Immunol 37 (1993) 155-158
43. Rolão N., Cortes S., Gomes-Pereira S., and Campino L. Leishmania infantum: mixed T-helper-1/T-helper-2 immune response in experimentally infected BALB/c mice. Exp Parasitol 115 (2007) 270-276
44. Wilson M.E., Sandor M., Blum A.M., Young B.M., Metwali A., Elliott D., et al. Local suppression of IFN-gamma in hepatic granulomas correlates with tissue-specific replication of Leishmania chagasi. J Immunol 156 (1996) 2231-2239
45. Ghalib H.W., Piuvezam M.R., Skeiky Y.A.W., Siddig M., Hashim F.A., El-Hassan A.M., et al. Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J Clin Invest 92 (1993) 324-329
46. Karp C.L., el-Safi S.H., Wynn T.A., Satti M.M., Kordofani A.M., Hashim F.A., et al. In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma. J Clin Invest 91 (1993) 1644-1648
47. Melby P.C., Yang Y.Z., Cheng J., and Zhao W. Regional differences in the cellular immune response to experimental cutaneous or visceral infection with Leishmania donovani. Infect Immun 66 (1998) 18-27
48. Murphy M.L., Wille U., Villegas E.N., Hunter C.A., and Farrell J.P. IL-10 mediates susceptibility to Leishmania donovani infection. Eur J Immunol 31 (2001) 2848-2856
49. Murray H.W., Moreira A.L., Lu C.M., DeVecchio J.L., Matsuhashi M., Ma X., et al. Determinants of response to interleukin-10 receptor blockade immunotherapy in experimental visceral leishmaniasis. J Infect Dis 188 (2003) 458-464
50. Murray H.W., Lu C.M., Mauze S., Freeman S., Moreira A.L., Kaplan G., et al. Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect Immun 70 (2002) 6284-6293
51. Marques-da-Silva E.A., Coelho E.A.F., Gomes D.C.O., Vilela M.C., Masioli C.Z., Tavares C.A.P., et al. Intramuscular immunization with p36(LACK) DNA vaccine induces IFN-γ production but does not protect BALB/c mice against Leishmania chagasi intravenous challenge. Parasitol Res 98 (2005) 67-74
52. Pinelli E., Gebhard D., Mommaas A.M., van Hoeij M., Langermans J.A.M., Ruitenberg E.J., et al. Infection of a canine macrophage cell line with Leishmania infantum: determination of nitric oxide production and anti-leishmanial activity. Vet Parasitol 2 (2000) 181-189
53. Panaro M.A., Acquafredda A., Lisi S., Lofrumento D.D., Mitolo V., Sisto M., et al. Nitric oxide production by macrophages of dogs vaccinated with killed Leishmania infantum promastigotes. Comp Immunol Microbiol Infect Dis 24 (2001) 187-195
54. Panaro M.A., Acquafredda A., Lisi S., Lofrumento D.D., Trotta T., Satalino R., et al. Inducible nitric oxide synthase and nitric oxide production in Leishmania infantum-infected human macrophages stimulated with interferon-gamma and bacterial lipopolysaccharide. Int J Clin Lab Res 29 (1999) 122-127
55. Gantt K.R., Goldman T.L., McCormick M.L., Miller M.A., Jeronimo S.M., Nascimento E.T., et al. Oxidative responses of human and murine macrophages during phagocytosis of Leishmania chagasi. J Immunol 167 (2001) 893-901
56. Deck R.R., DeWitt C.M., Donnelly J.J., Liu M.A., and Ulmer J.B. Characterization of humoral immune responses induced by an influenza hemagglutinin DNA vaccine. Vaccine 15 (1997) 71-78
57. Robinson H.L., Boyle C.A., Feltquate D.M., Morin M.J., Santoro J.C., and Webster R.G. DNA immunization for influenza virus: studies using hemagglutinin- and nucleoprotein-expressing DNAs. J Infect Dis 176 Suppl. 1 (1997) S50-S55
58. Dondji B., Perez-Gimenez E., Goldsmith-Pestana K., Esteban M., and McMahon-Pratt D. Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis. Infect Immun 73 (2005) 5286-5289
59. Corr M., Lee D.J., Carson D.A., and Tighe H. Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J Exp Med 184 (1996) 1555-1560
60. + cells in experimental visceral leishmaniasis. J Immunol 140 (1988) 3971-3977
61. Tsagozis P., Karagouni E., and Dotsika E. CD8 (+) T cells with parasite-specific cytotoxic activity and a Tc1 profile of cytokine and chemokine secretion develop in experimental visceral leishmaniasis. Parasite Immunol 25 (2003) 569-579
62. + T lymphocytes in a self-curing mouse model of visceral leishmaniasis. Parasitol Int 54 (2005) 139-146
63. Ramiro M.J., Zárate J.J., Hanke T., Rodriguez D., Rodriguez J.R., Esteban M., et al. Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK. Vaccine 21 (2003) 2474-2484
64. + T cell responses and protection against Leishmania major infection. J Exp Med 195 (2002) 1565-1573
65. Goto H., and Lindoso J.A.L. Immunity and immunosupression in experimental visceral leishmaniasis. Braz J Med Biol Res 37 (2004) 615-623
66. Wilson M.E., Jeronimo S.M.B., and Pearson R.D. Immunopathogenesis of infection with the visceralizing Leishmania species. Microb Pathog 38 (2005) 147-160